Adrb2, also known as the beta-2 adrenergic receptor, is a key component in adrenergic signaling pathways. It is involved in regulating various cellular processes such as cell proliferation, survival, apoptosis, and metabolism [1-3]. This signaling pathway is of great biological importance as it is implicated in numerous physiological and pathological conditions. Genetic models, especially gene knockout (KO) and conditional knockout (CKO) mouse models, can be valuable for studying Adrb2's functions.

In cancer research, Adrb2 signaling has been shown to contribute to the progression and therapy resistance of prostate cancer by inhibiting apoptosis [1]. In hepatocellular carcinoma (HCC), ADRB2 signaling promotes tumor progression and sorafenib resistance by negatively regulating autophagy, leading to HIF1α stabilization [2]. In gastric cancer, stress-hormone-induced activation of the ADRB2 signaling pathway plays a crucial role in tumor progression and metastasis, and ADRB2 antagonists can suppress these processes by inhibiting certain MAPK pathways and transcription factors [3]. In prostate cancer, intrinsic ADRB2 inhibition in CAR-T cells improves their therapeutic efficacy against the cancer [4]. In gastrointestinal stromal tumor (GIST), ADRB2 promotes cell proliferation, migration, invasion, and apoptosis, and silencing ADRB2 inhibits GIST progression and metastasis in nude mice [5].

In conclusion, Adrb2 plays essential roles in multiple biological processes, especially in cancer-related processes like tumor progression, metastasis, and treatment resistance. Research using KO/CKO mouse models or other in vivo models has revealed its significance in prostate, liver, gastric, and gastrointestinal stromal tumors, providing potential therapeutic targets for these diseases.